Skip to main content
OpenTrials
Completed

NCT Number: NCT05201313

Efficacy and Safety of the Application of Local Anaesthetic in Spray to Repair of 1st- 2nd Perineal Lacerations

Randomized controlled trial aimed at evaluating the efficacy and safety of the use of a local anesthetic spray, commonly used in clinical practice as off-label, during the suturing of perineal lacerations in post-partum, comparing it with the standard technique that involves the infiltration of lacerated tissues, by administering a NRS card at the end of the procedure.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The study aims to compare the effectiveness of pain treatment during the suturing of postpartum perineal lacerations with lidocaine spray vs skin infiltration. The hypothesis of the study is that the treatment of perineal pain with nebulization demonstrates comparable efficacy vs the infiltration of mepivacaine hydrochloride in a population of patients subjected to suturing of postpartum lacerations. Eligible women will be randomly assigned to receive, after wound disinfection and cleansing of bleeding with mild haemostasis:

  • nebulization 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm (experimental group).
  • subcutaneous / submucosal infiltration depending on the type of perineal laceration of 10 ml of 1% mepivacaine hydrochloride (control group).

Since there are no previous published studies, regarding the use of nebulized lidocaine hydrochloride for the suturing of perineal lacerations, the number of puffs chosen was chosen based on what is indicated on the technical data sheet of lidocaine hydrochloride and making use of previous studies in the gynecological field, but with other indications.

The suture will be made once anesthetic efficacy is achieved, as per pharmacological indications. The administration of the anesthetic and the suturing of the lacerations will be performed by the gynecologist or by the gynecology resident who will be working at that time in the delivery room, as is routinely done in our Clinic. The patients will be enrolled consecutively following the order generated by the randomization list itself. By filling in specific pre-set cards, the data will be collected.

Initially, the primary outcome was NRS at the beginning of suturing and NRS at the end of the procedure. In a second moment, the investigators thought it would be better to ensure that adequate analgesia (NRS<4) was achieved for all patients during suturing, rather than varying the dosage of the anesthetic itself. The investigators then decided to reassess pain at successive time points, evaluating it at 0, 2, 4, 12, and 24 hours.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • have a 1st or 2nd degree postpartum perineal laceration requiring suturing;
  • have reached 37 gestational weeks;
  • are over 18 years of age;
  • had a top birth;
  • are able to understand the Italian language;
  • have a consent to participate in the study;

Exclusion criteria

  • have received epidural anesthesia within 2 hours prior to delivery;
  • had an operative birth;
  • have a psychiatric pathology;
  • have had a twin birth;
  • have experienced adverse reactions to any local anesthetic in the past;
  • hypersensitivity to the active substance or to any of the excipients
  • Severe disturbances of the cardiac conduction system
  • Acute non compensated heart failure
  • Severe arteriopathies
  • Severe uncontrolled hypertension
  • Intravascular injections
  • Septicemia Dysfunction
  • Infection at the injection site
  • Kidney failure. Providing for the exclusion of patients with severe renal impairment (estimated GFR <30 mL / min / 1.73 m2 at the time of screening).
  • Advanced liver dysfunction
  • Hyperthyroidism
  • Acute angle glaucoma
  • Participation in a clinical trial in which an investigational drug was administered within 30 days of screening or 5 half-lives of the study drug
  • Any clinical condition that in the investigator's judgment would render the patient unsuitable for the study including, but not limited to, infectious, inflammatory, psychiatric, neurological, cardiological, renal, hepatic, respiratory, diabetes) conditions or laboratory value at clinically meaningful screening that, an investigator's opinion, may present a safety risk, interface with study compliance and follow-up;
  • have had in pregnancy liver disease including pre-eclampsia.

Treatment and study plan

Lidocaine Hydrochloride

Drug

nebulization of 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm

Other names: ECOCAIN

Mepivacaine Injection

Drug

subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride

Other names: MEPIVACAINA CLORIDRATO

Primary outcomes

  1. NRS 2

    Time frame: At 2 hours after delivery

    numeric rating scale for pain (0=no pain-10=maximum pain)

  2. NRS 4

    Time frame: At 4 hours after delivery

    numeric rating scale for pain (0=no pain-10=maximum pain)

  3. NRS 12

    Time frame: At 12 hours after delivery

    numeric rating scale for pain (0=no pain-10=maximum pain)

  4. NRS 24

    Time frame: At 24 hours after delivery

    numeric rating scale for pain (0=no pain-10=maximum pain)

  5. NRS o

    Time frame: during suturing

    numeric rating scale for pain (0=no pain-10=maximum pain)

Secondary outcomes

  1. need for additional doses (number of additional nebulizations, presence or absence of additional infiltration)

    Time frame: during the suture

    need for an additional dose of nebulization and / or additional infiltration during the suturing of the postpartum perineal laceration

  2. final satisfaction, assessed via telephonic interview

    Time frame: 30 days follow up

    satisfaction of the puerpera, assessed through the 30 days-follow up, asking for the patient's opinion regarding postpartum pain and any long-term complications

Sponsors and collaborators

Lead sponsor

Azienda Sanitaria-Universitaria Integrata di Udine

Other

Registry information

Official study title

Randomised Controlled Trial to Evaluate the Efficacy of Local Anaesthetic Application in Spray for the Repair of 1st- 2nd Perineal Lacerations Following Vaginal Delivery

Acronym: LISPRAY

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Jan 21, 2022
Registry last updated
Sep 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.